Total Neoadjuvant Therapy

AI Model Shows Moderate Accuracy for Predicting Complete Response After Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

By MedXY 06/08/2026

A fine-tuned ensemble of tabular foundation models moderately predicted pathological complete response after TNT and showed potential to support watch-and-wait selection after recalibration.

Gastroenterology news Oncology

Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial

By MedXY 11/29/2025

The NO-CUT phase 2 trial shows that total neoadjuvant therapy (CAPOX-based TNT) followed by non-operative management for clinical complete responders achieved high 30‑month distant relapse‑free survival (95%) and enabled organ preservation in 26% of patients with pMMR/MSS stage II–III rectal cancer.

Oncology Specialties

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Real-World Insights from an International Consortium

By MedXY 08/23/2025

This international multicenter study evaluates total neoadjuvant therapy (TNT) in routine clinical practice for stage II/III rectal adenocarcinoma, demonstrating varied regimen use and confirming TNT’s efficacy across treatment strategies.

Clinical Updates General Surgery Oncology Specialties

Advancing Organ Preservation in Locally Advanced Rectal Cancer: Insights from the CAO/ARO/AIO-16 Phase 2 Trial

By MedXY 08/14/2025

Total neoadjuvant therapy combined with watch-and-wait strategies achieves a 37% clinical complete response rate in locally advanced rectal cancer with manageable toxicity, offering an organ-preserving alternative to surgery.